These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35279606)

  • 1. Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT
    Ma M; Yang Y; Du G; Dai Y; Zhu X; Wang W; Xu H; Zhang J; Zheng L; Zou F; Yang H; Liu B; Liu W; Ye L; Zhang R; Tian J
    Eur J Med Chem; 2022 Apr; 234():114246. PubMed ID: 35279606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, Molecular Docking, and Biological Evaluation of Novel Pimavanserin-Based Analogues as Potential Serotonin 5-HT
    Albujuq NR; Meana JJ; Diez-Alarcia R; Muneta-Arrate I; Naqvi A; Althumayri K; Alsehli M
    J Med Chem; 2023 Jul; 66(13):9057-9075. PubMed ID: 37378639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
    Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
    Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
    McFarland K; Price DL; Bonhaus DW
    Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [No Abstract]   [Full Text] [Related]  

  • 9. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.
    Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N
    J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
    Stahl SM
    CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
    Isaacson SH; Coate B; Norton J; Stankovic S
    J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual 5-HT
    Oguma T; Jino K; Nakahara K; Asada H; Fuchino K; Nagatani K; Kouki K; Okamoto R; Takai N; Koda K; Fujita S; Sekiguchi Y; Yasuo K; Mayumi K; Abe A; Imono M; Horiguchi N; Iwata S; Kusakabe KI
    J Med Chem; 2024 Aug; 67(16):14478-14492. PubMed ID: 39137033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of 5-HT
    Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
    Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimavanserin: First Global Approval.
    Markham A
    Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Norton JC; Chi-Burris K; Demos G
    CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.